In this roundtable discussion at the 65th American Society of Hematology Annual Meeting & Exposition, Drs. Hana Safah, Jamile Shammo, Andrew Brunner, and Tiffany Tanaka share their outlook for the future of myelodysplastic syndromes research and treatments. Watch here: https://buff.ly/4aV7vB8
Heme Today’s Post
More Relevant Posts
-
In case you missed the myelodysplastic syndromes roundtable at the 2023 American Society of Hematology Annual Meeting, Drs. Hana Safah, Jamile Shammo, Andrew Brunner, and Tiffany Tanaka cover a study that compared luspatercept and epoetin alfa in myelodysplastic syndromes. Watch the full roundtable: https://buff.ly/3NSI9d8
-
-
Executive Vice-President and Chief Medical Officer, CLL Society, Inc., a 501c3 dedicated to the unmet needs of the chronic lymphocytic community (CLL)
Should be an informative webinar for patient and doctor alike who are invested in the latest research from ASH 2023 on CLL/SLL
Our ASH 2023 Comes to You webinar is one week away on Jan. 26th! Join CLL expert Dr. Nicole Lamanna and Dr. Brian Koffman as they discuss important CLL research and clinical trial data that was presented at the American Society of Hematology (ASH) Annual Meeting that took place in December 2023. Learn more and register at: https://bit.ly/3ROI3nQ
-
-
Excited to share preliminary data from the Century Therapeutics, Inc ELiPSE-1 trial and a case study of a patient who maintained a CR while receiving four 28 day cycles of CNTY-101 at the lowest dose level. CNTY-101 is engineered with six precision edits, including ALLO-EVASION technology to enable repeat dosing. Importantly, this patient's first two cycles included lymphodepletion while the next two did not. No pre-existing or induced anti-drug antibodies were detected and each infusion demonstrated comparable kinetics. These early results are encouraging for both oncology and non-oncology indications, where the side effect profile of lymphodepletion may be prohibitive. #ipsc #celltherapy #geneediting #oncology #autoimmune
We look forward to presenting initial data from our ongoing first-in-human Phase 1 ELiPSE-1 trial of CNTY-101 in relapsed/refractory CD19 positive B-cell #lymphomas at the 65th American Society of Hematology Annual Meeting and Exposition on December 9, 2023 in San Diego. Read the press release: https://bit.ly/3Mr8f6u
-
-
Join Dr. Raajit K. Rampal for an oral session at the 2023 American Society of Hematology Annual Meeting TODAY at 5:15pm PST. Dr. Rampal will present a phase III study on myelofibrosis, which seeks to compare ruxolitinib, the main standard of care treatments for this disease, to the combination of ruxolitinib and Pelabresib (a novel BET inhibitor). Learn more here: https://bit.ly/4abVmY6
-
-
Today we presented real-world evidence evaluating a CD-19-directed antibody for relapsed or refractory DLBCL at the American Society of Hematology Annual Meeting. Check out the abstract to learn more. #ASH23 https://bit.ly/47KZjkM
DLBCL Data at ASH 2023
-
NEW #Thalassemia Sessions from #ASH23🩸 💬 In this session, leading experts Maria Domenica Cappellini & Kevin Kuo discuss exciting updates in #thalassemia presented at the 2023 ASH Annual Meeting and Exposition The experts cover several topics, including the promise of novel #genetherapies, ongoing #clinicaltrials in the field, and the value of #precisionmedicine 🔬 Take a look 👉 https://lnkd.in/e2-JsM7Y #HemOnc #MPNsm American Society of Hematology
-
-
NEW #MPN Session from #ASH23🩸 💬 This EXCLUSIVE discussion features leading experts Ruben Mesa, MD, Claire Harrison & Jean-Jacques Kiladjian, who discuss key updates in the #treatment and #management of #myeloproliferativeneoplasms (#MPNs) following the 65th ASH Annual Meeting and Exposition The experts cover a variety of topics, including #novelagents being explored in essential #thrombocythemia (ET), updates in the treatment of #polycythemiavera (PV), and novel combinations being evaluated in #myelofibrosis (MF) 🔦 Take a look 👉 https://lnkd.in/eXeXjSFj #HemOnc #MPNsm American Society of Hematology
-
-
How can your laboratory help reduce unnecessary complications for newly diagnosed Multiple Myeloma patients? Find out how from Prof. Guy Pratt who discusses how your laboratory can help guide blood test requesting and appropriate hematology referral. Download our case studies from hospitals in the United Kingdom, United States and Spain by here: https://hubs.li/Q02phTNn0
-
-
📢All 12 manuscripts in the #SpecialIssue “#Hematologic #Malignancies: Challenges from Diagnosis to Treatment”, led by Dr. Ioanna Sakellari and Dr. Eleni Gavriilaki, Hematology Department and Dr. Eleni Gavriilaki, have been published! 🎉🎉 📌You are welcome to read via the following link: https://lnkd.in/dyADYnGy
-
-
some basics of micro
Medical Laboratory Scientist 🩸🔬- MSc, MLS (ASCPi), ISC(ASCPi) - Founder and CEO of TAG Academy
- Color Atlas of Monica Book (Micro and Hematology) #tag_academy #gaber_notes